BANK VONTOBEL/PUT/ELI LILLY & CO/720/0.1/20.09.24 | Delayed Deutsche Boerse AG 01:41:50 2024-07-16 pm EDT | ||
| 0.183 EUR | -8.50% |
|
| Current month | -50.54% | ||
| 1 month | -70.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.183 | -8.50% |
| 24-07-15 | 0.2 | +2.04% |
| 24-07-12 | 0.196 | -14.78% |
| 24-07-11 | 0.23 | +11.11% |
| 24-07-10 | 0.207 | -10.00% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 01:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM92QP |
| ISIN | DE000VM92QP7 |
| Date issued | 2024-02-08 |
| Strike | 720 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 10 : 1 |
| Emission price | 4.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.44 € |
|---|---|
| Lowest since issue | 0.171 € |
| Spread | 0.018 € |
| Spread % | 8.14% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Warrants
- Warrant
